| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
STARLING REVIEW |  |
The Kinsey Institute, Indiana University, Morrison Hall third floor, Bloomington, Indiana 47405, USA
(Requests for offprints should be addressed to J Bancroft; Email: jbancrof{at}indiana.edu)
The relevance of testosterone, oestradiol and certain peptides (oxytocin (OT), ß-endorphin and prolactin (PRL)) to sexual arousal in humans is reviewed. In addition to behavioural studies, evidence of distribution of gonadal steroid receptors in the brain and the limited evidence from brain imaging are also considered. Testosterone plays a key role in the adult male, with clear, consistent evidence from studies of hypogonadal and eugonadal men. The roles of testosterone in the development of sexual arousability, and in the aging male, are less clear. The relevance of aromatization and of non-sexual effects of testosterone which might indirectly influence sexual arousal are not well understood. Testosterone in the female presents a more complex, less consistent picture. One possible explanation is a much greater variability across women in responsiveness to testosterone. A ‘desensitization hypothesis’ to account for the striking gender differences is offered. There is limited evidence of a direct effect of oestradiol on sexual arousability in women. The extent to which testosterone in women acts by conversion to oestradiol or by increase of free oestradiol is not yet clear. The role of peptides in sexual arousal remains uncertain, partly because of the multiple roles and sites of action of most peptides. OT and ß-endorphin appear to have both excitatory and inhibitory effects. PRL has been proposed as an inhibitory factor via direct inhibition of dopaminergic activity, but the evidence for this is inconclusive. Whereas the traditional concept of ‘hormone’ continues to apply to the role of testosterone and oestradiol in sexual arousal, peptides present a more complex role.
This article has been cited by other articles:
|
|
 |
|
  F Jockenhovel, T Minnemann, M Schubert, S Freude, D Hubler, C Schumann, A Christoph, and M Ernst Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men Eur. J. Endocrinol., May 1, 2009; 160(5): 815 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Giltay and L. J. G. Gooren Potential Side Effects of Androgen Deprivation Treatment in Sex Offenders J Am Acad Psychiatry Law, March 1, 2009; 37(1): 53 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Soukhova-O'Hare, Z. A. Shah, Z. Lei, A. D. Nozdrachev, C. V. Rao, and D. Gozal Erectile Dysfunction in a Murine Model of Sleep Apnea Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 644 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Talbot, R. Sheldrick, H. Caswell, and S. Duncan Sexual function in men with epilepsy: How important is testosterone? Neurology, April 15, 2008; 70(16): 1346 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Thakur and V. K. Dixit Aphrodisiac Activity of Dactylorhiza hatagirea (D.Don) Soo in Male Albino Rats Evid. Based Complement. Altern. Med., September 1, 2007; 4(suppl_1): 29 - 31. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H.J. Bancroft Sex and Aging N. Engl. J. Med., August 23, 2007; 357(8): 820 - 822. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zitzmann, S. Faber, and E. Nieschlag Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4335 - 4343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Armagan, N. N. Kim, I. Goldstein, and A. M. Traish Dose-Response Relationship Between Testosterone and Erectile Function: Evidence for the Existence of a Critical Threshold J Androl, July 1, 2006; 27(4): 517 - 526. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
